Pharma Equities Technical Analysis -- Sanofi, AstraZeneca, Novartis, Salix Pharma, and AcelRx Pharma

LONDON, August 26, 2014 /PRNewswire/ --

On Monday, August 25, 2014, the NASDAQ Composite ended at 4,557.35, up 0.41%, the Dow Jones Industrial Average finished the day 0.44% higher at 17,076.87, and the S&P 500 closed at 1,997.92, up 0.48%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 732.60, up 0.72%, with the index gaining 7.53% in the previous three months. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

Sanofi's stock finished Monday's session 1.97% higher at $53.72. A total of 0.74 million shares were traded, which was below its three months average volume of 1.05 million shares. The stock vacillated between $53.04 and $53.88 during the session. Over the previous three trading sessions and over the last one month, Sanofi's shares have gained 1.76% and 5.40%, respectively. Additionally, in the previous three months, the stock has advanced 1.76%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $52.64 is greater than its 200-day moving average of $51.97. Sanofi's stock has a Relative Strength Index (RSI) of 50.60. Sign up and read the free notes on SNY at:

http://www.Investor-Edge.com/SNY-26Aug2014

On Monday, shares in AstraZeneca PLC fluctuated between $73.37 and $73.98 before ending the session 1.15% higher at $73.89. The stock reported a trading volume of 1.76 million shares, below its three months average volume of 2.95 million shares. AstraZeneca PLC's shares have gained 4.07% in the previous three trading sessions, 2.23% in the last three months and 24.46% on YTD basis. The shares are trading above its 50-day and 200-day moving averages of $73.27 and $66.98, respectively. Moreover, shares of AstraZeneca PLC have an RSI of 56.89. The complimentary notes on AZN can be downloaded as in PDF format at:

http://www.Investor-Edge.com/AZN-26Aug2014

Novartis AG's stock edged 0.18% higher, to close the day at $89.11. The stock recorded a trading volume of 0.78 million shares, below its three months average volume of 1.20 million shares. The company's shares oscillated between $88.83 and $89.48 during the session. Over the last three trading sessions and over the past one month, Novartis AG's shares have advanced 0.58% and 0.79%, respectively. Further, the stock has gained 10.86% since the start of this year. The shares are trading above its 50-day and 200-day moving averages of $88.88 and $84.16, respectively. Additionally, Novartis AG's stock has an RSI of 59.21. Register for free on Investor-Edge and access the latest research on NVS at:

http://www.Investor-Edge.com/NVS-26Aug2014

On Monday, shares in Salix Pharmaceuticals Ltd recorded a trading volume of 0.81 million shares, lower than its three months average volume of 1.31 million shares. The stock ended the day at $157.90, which was 0.67% below its previous day's closing of $158.96, and registered an intraday range of $157.74 and $160.32. Shares of the company traded at a PE ratio of 88.19. Salix Pharmaceuticals Ltd's stock has surged 19.42% in the last one month, 38.29% in the previous three months, and 75.56% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $132.59 and $108.20, respectively. Furthermore, shares of Salix Pharmaceuticals Ltd have an RSI of 73.87. The complete research on SLXP is available for free at:

http://www.Investor-Edge.com/SLXP-26Aug2014

Shares in AcelRx Pharmaceuticals Inc. advanced 1.36% to end Monday's session at $6.70. The stock recorded a trading volume of 0.64 million shares, below its three months average volume of 1.12 million shares. The company's shares fluctuated between $6.56 and $6.90 during the session. AcelRx Pharmaceuticals Inc.'s shares have declined 38.13% in the last one month and 40.76% since the start of this year. However, the stock has gained 4.36% over the previous three trading sessions. The stock is trading below its 50-day and 200-day moving averages. AcelRx Pharmaceuticals Inc.'s 200-day moving average of $10.04 is above its 50-day moving average of $8.85. Additionally, the stock has an RSI of 40.03. Free in depth research on ACRX is available at:

http://www.Investor-Edge.com/ACRX-26Aug2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED